Valuation: SpectraCure AB

Market Cap 28.47M 2.95M 2.58M 2.38M 2.2M 4.18M 282M 4.25M 11.18M 139M 11.09M 10.85M 477M P/E 2024
-10.6x
P/E 2025 -0.79x
Enterprise Value 17.74M 1.84M 1.61M 1.48M 1.37M 2.6M 175M 2.65M 6.97M 86.45M 6.91M 6.76M 297M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
85.17%
Yield 2024 *
-
Yield 2025 -
1 day-0.40%
1 week-21.79%
Current month-9.27%
1 month-58.90%
3 months-41.16%
6 months-58.83%
Current year-67.97%
1 week 0.05
Extreme 0.0483
0.07
1 month 0.04
Extreme 0.0403
0.09
Current year 0.04
Extreme 0.0403
0.17
1 year 0.04
Extreme 0.0403
0.32
3 years 0.04
Extreme 0.0403
6.4
5 years 0.04
Extreme 0.0403
13.19
10 years 0.04
Extreme 0.0403
45.15
Manager TitleAgeSince
Chief Executive Officer 54 2025-09-30
Director of Finance/CFO - 2026-05-31
Chief Tech/Sci/R&D Officer - 2025-10-06
Director TitleAgeSince
Director/Board Member 72 2021-12-31
Director/Board Member 63 2012-08-30
Chairman 74 2021-12-31
Date Insider Type Main position Quantity % Market Cap.
23-05-25Buy

Chairman

25,000 0.0257%
22-08-29Buy

Director

25,000 0.0257%
22-07-08Buy

Director

1,048,493 1.0795%
Change 5-day change 1-year change 3-year change Capi.($)
-0.40%-21.79%-79.72%-99.18% 2.95M
-0.85%-6.52%+39.90%+47.87% 1.5B
+1.11%-3.11%-43.16%-51.92% 286M
-5.45%0.00%+33.33%-8.77% 54.37M
+3.24%-0.45%-8.00%-49.77% 54.16M
Average -0.47%-6.37%-11.53%-32.35% 379.04M
Weighted average by Cap. -0.57%-5.67%+25.60%+28.14%

Financials

2024 2025
Net sales - -
Net income -23M -2.39M -2.09M -1.93M -1.78M -3.37M -228M -3.43M -9.03M -112M -8.96M -8.77M -385M -56.08M -5.82M -5.09M -4.69M -4.33M -8.23M -555M -8.36M -22.02M -273M -21.84M -21.37M -940M
Net Debt -13.13M -1.36M -1.19M -1.1M -1.01M -1.93M -130M -1.96M -5.16M -63.99M -5.11M -5M -220M -10.74M -1.11M -974K -899K -830K -1.57M -106M -1.6M -4.22M -52.33M -4.18M -4.09M -180M
Logo SpectraCure AB
SpectraCure AB (publ) is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company specializes in cancer treatment technology. The Company develops photodynamic therapeutics based on photosensitive materials activated by laser. The Company's method is called interstitial photodynamic therapy (PDT). Interstitial PDT can be used for solid tumors in internal organs, such as cancer in the prostate, pancreas, and the head and neck area, among others. In addition, the Company offers software platform IDOSE for interstitial PDT treatment of solid cancer tumors in internal organs. With SpectraCure’s interstitial PDT method, the patient is given a photoactivated drug - photosensitizer in combination with laser light guided by a dose control system.
Employees
13
Date Price Change Volume
26-07-10 SEK 0.0499 -0.40% 1,397,816
26-07-09 SEK 0.0501 -4.21% 2,078,790
26-07-08 SEK 0.0523 -10.14% 1,608,067
26-07-07 SEK 0.0582 -9.06% 1,326,928
26-07-06 SEK 0.0640 +0.31% 1,214,291
  1. Stock Market
  2. Stocks
  3. SPEC Stock